Immunome (IMNM) Assets Average (2020 - 2026)

Immunome has reported Assets Average for 7 years, with the latest figure at $651.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 123.52% year-over-year to $651.5 million; the trailing twelve-month figure through Mar 2026 stood at $651.5 million (up 123.52% YoY), and the FY2025 full-year result was $461.7 million, up 137.52% from the prior year.
• Assets Average for Q1 2026 stood at $651.5 million, up from $491.3 million in the prior quarter.
• The five-year high for Assets Average was $651.5 million in Q1 2026, with the low at $27.3 million in Q4 2022.
• Historically, Assets Average has averaged $208.6 million across 5 years, with a median of $234.1 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average sank 54.69% — and 2024, when it jumped 587.86%.
• Immunome's Assets Average stood at $27.3 million in 2022, then soared by 342.74% to $120.9 million in 2023, then jumped by 105.68% to $248.6 million in 2024, then jumped by 97.64% to $491.3 million in 2025, then surged by 32.61% to $651.5 million in 2026.
• The last three Assets Average figures came in at $651.5 million (Q1 2026), $491.3 million (Q4 2025), and $297.8 million (Q3 2025), per Business Quant data.